SCPHARMACEUTICALS INC. - COMMON STOCK

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

10 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

13 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

15 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

14 авг 2024 15:01:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

12 авг 2024 08:48:52 Источник Nasdaq GlobeNewswire

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

12 авг 2024 05:05:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

12 авг 2024 05:04:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

12 авг 2024 05:02:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

12 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

08 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease

25 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

29 май 2024 15:01:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

14 май 2024 15:01:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 май 2024 15:05:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

07 май 2024 15:05:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

24 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

13 мар 2024 15:01:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

06 мар 2024 15:01:00 Источник Nasdaq GlobeNewswire

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

28 фев 2024 15:01:00 Источник Nasdaq GlobeNewswire